Related Experiment Video
Updated: Feb 22, 2026
Microfluidic Device for Recreating a Tumor Microenvironment in Vitro
Published on: November 20, 2011
Differential response to doxorubicin in breast cancer subtypes simulated by a microfluidic tumor model
Altug Ozcelikkale1, Kyeonggon Shin1, Victoria Noe-Kim1
1School of Mechanical Engineering, Purdue University, West Lafayette, IN, USA.
Abstract:
Successful drug delivery and overcoming drug resistance are the primary clinical challenges for management and treatment of cancer. The ability to rapidly screen drugs and delivery systems within physiologically relevant environments is critically important; yet is currently limited due to lack of appropriate tumor models. To address this problem, we developed the Tumor-microenvironment-on-chip (T-MOC), a new microfluidic tumor model simulating the interstitial flow, plasma clearance, and transport of the drug within the tumor. We demonstrated T-MOC's capabilities by assessing the delivery and efficacy of doxorubicin in small molecular form versus hyaluronic acid nanoparticle (NP) formulation in MCF-7 and MDA-MB-231, two cell lines representative of different molecular subtypes of breast cancer. Doxorubicin accumulated and penetrated similarly in both cell lines while the NP accumulated more in MDA-MB-231 than MCF-7 potentially due to binding of hyaluronic acid to CD44 expressed by MDA-MB-231. However, the penetration of the NP was less than the molecular drug due to its larger size. In addition, both cell lines cultured on the T-MOC showed increased resistance to the drug compared to 2D culture where MDA-MB-231 attained a drug-resistant tumor-initiating phenotype indicated by increased CD44 expression. When grown in immunocompromised mice, both cell lines exhibited cell-type-dependent resistance and phenotypic changes similar to T-MOC, confirming its predictive ability for in vivo drug response. This initial characterization of T-MOC indicates its transformative potential for in vitro testing of drug efficacy towards prediction of in vivo outcomes and investigation of drug resistance mechanisms for advancement of personalized medicine.
Insights
A novel microfluidic Tumor-microenvironment-on-chip (T-MOC) model accurately predicts in vivo cancer drug response and resistance. This advanced tumor model aids in developing personalized cancer medicine and drug delivery systems.
Area of Science:
- Biomedical Engineering
- Cancer Research
- Drug Delivery Systems
Background:
- Overcoming cancer drug resistance and ensuring effective drug delivery are critical clinical challenges.
- Current tumor models lack the physiological relevance needed for accurate drug screening and resistance studies.
- Developing advanced in vitro models is essential for predicting in vivo drug efficacy and understanding resistance mechanisms.
Purpose of the Study:
- To develop and validate a Tumor-microenvironment-on-chip (T-MOC) model that simulates key aspects of the tumor microenvironment.
- To assess the delivery, efficacy, and resistance patterns of doxorubicin using both molecular and nanoparticle formulations within the T-MOC.
- To confirm the T-MOC's predictive capability for in vivo drug response and its utility in studying cancer drug resistance.
Main Methods:
- Development of a microfluidic Tumor-microenvironment-on-chip (T-MOC) device simulating interstitial flow, plasma clearance, and drug transport.
- Assessment of doxorubicin delivery and efficacy in MCF-7 and MDA-MB-231 breast cancer cell lines using molecular and nanoparticle formulations.
- Comparison of drug response and phenotypic changes in T-MOC with 2D cultures and in vivo mouse models.
Main Results:
- The T-MOC model successfully simulated drug delivery and accumulation, with nanoparticles showing differential accumulation based on cell surface markers (CD44).
- Both cell lines exhibited increased drug resistance in the T-MOC compared to 2D cultures, with MDA-MB-231 cells developing a resistant phenotype.
- T-MOC results correlated with in vivo observations in mice, confirming its predictive power for drug response and resistance.
- Nanoparticle drug delivery showed reduced penetration compared to molecular doxorubicin due to particle size.
Conclusions:
- The Tumor-microenvironment-on-chip (T-MOC) is a powerful, physiologically relevant model for evaluating cancer drug delivery and efficacy.
- T-MOC facilitates the investigation of drug resistance mechanisms and predicts in vivo outcomes, advancing personalized cancer medicine.
- This microfluidic platform holds transformative potential for preclinical drug screening and therapeutic development.
